<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="757">
  <stage>Registered</stage>
  <submitdate>16/09/2005</submitdate>
  <approvaldate>23/09/2005</approvaldate>
  <actrnumber>ACTRN12605000494639</actrnumber>
  <trial_identification>
    <studytitle>Impact of HIV and its treatment on reverse cholesterol transport</studytitle>
    <scientifictitle>Impact of HIV infection and treatment with Highly Active Antiretroviral therapy on Reverse Cholesterol Transport</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>HIV </healthcondition>
    <healthcondition>Atherosclerosis</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To compare untreated HIV-infected patients (patients who will not require therapy for the entire study duration of 12 months) with:
HIV-infected patients that are PI naÃ¯ve and initiating therapy with a protease inhibitor containing HAART regime (ARV naÃ¯ve or NNRTI experienced changing to PI regimen) at study baseline
and:
HIV-infected patients naÃ¯ve to ARV therapy and initiating NNRTI-containing regimen at baseline of the study.
The participants will remain in the study for a durtation of 12 months on the same medication as at baseline. This study will not influence the therapeutic management of the participants. Patients who have to change therapy during the study with be withdrawn.</interventions>
    <comparator />
    <control>Uncontrolled</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To investigate the effect of treatment of HIV infection with highly active antiretroviral therapy on reverse cholesterol transport in HIV-infected patients in a prospective study over a 12 month period.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1.To investigate the effect of treatment of HIV infection with highly active antiretroviral therapy on individual steps of reverse cholesterol transport in HIV-infected patients.</outcome>
      <timepoint>Over a 12 month period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2.To investigate the effect of treatment of HIV infection with highly active antiretroviral therapy on endothelial function in HIV-infected patients.</outcome>
      <timepoint>Over a 12 month period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. To investigate the effect of treatment of HIV infection with highly active antiretroviral therapy on intima-media thickness (atherosclerotic development) in HIV-infected patients.</outcome>
      <timepoint>Over a 12 month period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4.To analyse factors which determine the rate of reverse cholesterol transport in HIV patients naive to therapy and during treatment with HAART.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>5. To correlate use of protease inhibitors with defects in reverse cholesterol transport and clinical markers of atherosclerosis.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Male patients with HIV infection. 3 groups of 50 patients each. HIV infected patients, naive to ARV therapy and not likely to need to commence therapy for the duration of follow-up (12 months). HIV-infected patients, PI naive, initiating therapy with PI-containing HAART (ARV naÃ¯ve or NNRTI experienced changing to PI regimen). HIV-infected patients naive to ARV therapy, initiating NNRTI-containing regimen. </inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Treatment with any form of lipid lowering drugs, including fish oils. Body Mass Index greater than 27.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/06/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Health and Medical Research Council of Australia (grants # 317811 and 317810(DS)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council of Australia (grants # 317811 and 317810(DS)</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Baker Heart Research Institute</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Dmitri Sviridov</name>
      <address>Lipoproteins and Atherosclerosis Laboratory
Baker Heart Research Institute
Commercial Rd
Prahran VIC 3181</address>
      <phone>+61 3 85321363</phone>
      <fax>+61 3 85321100</fax>
      <email>Dmitri.Sviridov@baker.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor Jennifer Hoy</name>
      <address>Infectious Diseases Unit
Alfred Hospital
2nd Floor
Burnet Institute
Commercial Rd
Prahran VIC 3004</address>
      <phone>+61 3 92766900</phone>
      <fax>+61 3 92762431</fax>
      <email>Jennifer.Hoy@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>